Стан імунної системи у хворих на меланому хоріоїдеї на різних стадіях захворювання

D.A. Drumi

doi:10.31288/oftalmolzh202462732

Authors

D.A. Drumi SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"

DOI:

https://doi.org/10.31288/oftalmolzh202462732

Keywords:

choroidal melanoma, immune status, choroiditis, ocular oncology, immunology

Abstract

Purpose: To perform a pre-treatment comparison of patients with different stages of choroidal melanoma (CM) for humoral and cell-mediated immune status.
Material and Methods: This immune status study included 35 patients with T1 CM (group 1) and 31 patients with T1 to T3 CM (group 2) who were treated at the State Institution “The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine”. These patients were compared with 44 practically healthy individuals (group 3 or controls) for immune status. Immunologic evaluation of peripheral blood included absolute counts and percentages of leukocytes, lymphocytes, CD3+ T cells, CD4+ T helpers, CD8+ T suppressors, CD19+ B cells, СD16+ natural killer (NK) cells, phagocytic neutrophil activity (PNA), and imminoglobulins (Ig) A, M and G.
Results: Pre-treated patients in groups 1 and 2 had significantly increased absolute counts of leukocytes (p1-3 = 0.005 and p2-3 = 0.0003, respectively), lymphocytes (p1-3 = 0.04 and p2-3 = 0.0002, respectively), and cytotoxic CD8+ T suppressors (p1-3 = 0.0002 and p2-3 = 0.001, respectively), and CD4+/CD8+ ratio (p1-3 = 0.00002 and p2-3 = 0.0000, respectively), and PNA (p1-3 = 0.0004 and p2-3 = 0.0001, respectively), IgA (p1-3 = 0.003 and p2-3 = 0.009, respectively), and IgM (p1-3 = 0.0007 and p2-3 = 0.0000, respectively). There was, however, no significant difference in other parameters between patients and controls. Compared to patients in group 1 and controls, patients in group 2 had significantly increased absolute counts of CD4+ T helpers (p1-2 = 0.02 and p2-3 = 0.0000, respectively), СD16+ NK cells (p1-2 = 0.03 and p2-3 = 0.003, respectively), and IgM levels (p1-2 = 0.02 and p2-3 = 0.0000, respectively), and significantly decreased IgG levels (p1-2 = 0.006 and p2-3 = 0.003, respectively).
Conclusion: In pre-treatment patients differing in the stage of CM, the tumor process responds to immune changes that are expressed by activation of humoral and cell-mediated immunity (an increase in the activity of CD3+ T cells, CD4+ T-helpers, CD8+ T-suppressors, CD16+ NK cells, and IgM and IgA levels), which may have a substantial impact on treatment effect.

References

Velychko LM. [Immunologic effects of interferon]. Oftalmol Zh. 1997; 6:449-52. Russian.

Velychko LM, Vit VV, Maletskyi AP, Dragomyretska OI. [Immune correction with alfa-2beta interferon is an important component of treatment for uveal melanoma]. Onkologiia. 2000;2(2):64-7. Russian.

Velychko LM. [Immune correction with alfa-2beta interferon for optimized treatment for uveal melanoma]. Abstract of Cand Sc (Med) Thesis . Odesa: Filatov Institute of Eye Disease; 2000. Ukrainian.

Velychko LM. [Expression of molecular markers of activation of peripheral blood lymphocytes in patients differing in efficacy of eye-preserving treatment for uveal melanoma]. Oftalmol Zh. 2013;5:9-13. Russian.

Velychko LM. [Immunopathogenetic mechanisms of tumor process progression and their correction during eye-preserving treatment for uveal melanoma]. Abstract of Dr Sc (Med) Dissertation. Odesa: Filatov Institute of Eye Disease; 2018. Ukrainian.

Vit VV. [Prognostic role of morphological characteristics of the immune response in uveal melanoblastomas of various cellular types]. Arkh Patol. 1983; 45(7):25-30. Russian.

Maletskiĭ AP, Vit VV, Vanichkin OA. [Characteristics of the immune status of patients with uveal melanoma during the performance of organ-preserving treatment]. Oftalmol Zh. 1989;6:341-6. Russian.

Maletskyi AP, Voronkova AL, Gavrina GB. [Changes in immune reactivity during eye-preserving treatment for uveal melanoma as indicated by serum growth factors]. Oftalmol Zh. 1997;1:34-8. Russian.

Maletskyi AP. [Efficacy of iterpherone therapy combined with photocoagulation of tumor margins in patients with uveal melanoma]. Onkologiia. Russian.

Maletskyi AP. [Efficacy of organ-saving treatment of uveal melanoma patients depending on clinical and morphological characteristics of the tumor and body resistance to the tumor]. Abstract of Dr Sc (Med) Dissertation . Odesa: Filatov Institute of Eye Disease;2001. Ukrainian.

Male D, Brostoff J, Roth D, Roitt I, editors. [Immunology]. Logosfera: Moscow; 2007. Russian.

Poliakova SI, Velichko LM, Bogdanova AV, Tsukanova IV. Natural antitumor resistance of the organism condition of patients with uveal melanoma of small sizes. J Ophthalmol (Ukraine). 2016;1:27-30. https://doi.org/10.31288/oftalmolzh201612730

Poliakova SI, Velichko LM, Bogdanova AV, Tsukanova IV. Comparison of expression of molecular markers of peripheral blood lymphocyte activation in patients with small uveal melanoma and healthy controls. J Ophthalmol (Ukraine). 2017;1:25-8. https://doi.org/10.31288/oftalmolzh201712528

Poliakova SI, Velychko LM, Bogdanova AV, Tsukanova IV. [Immune status in patients with small choroidal melanoma]. In: In: [Proceedings of the Conference commemorating the 80th anniversary of the Filatov Institute and 14th Congress of the Black Sea Ophthalmological Society]. May 19-20, 2016. Odesa, Ukraine. Ukrainian.

Poliakova SI, Velychko LM, Bogdanova AV, Tsukanova IV. [Expression of molecular markers of peripheral blood lymphocyte activation in patients with small (T1) choroidal melanoma]. In: [Proceedings of the Filatov Memorial Lectures, Ophthalmology Conference with International Speakers]. May 25-26, 2017. Odesa, Ukraine.

Buiko OS, compiler and translator. [On the American Joint Commission on Cancer (AJCC) (7th edition) classification of choroidal melanoma]. Oftalmol Zh. 2010; 6:20-30. Russian.

Male D, Brostoff J, Roth D, Roitt I, editors. 5th ed. [Immunology]. Mir: Moscow; 2000. Russian.

Degtiarenko TV, Bushuieva NM, Usov NI. [Guidelines on prompt primary assessment of the immune status]. Odesa;1999. Russian.

Gluzman DF, Skliarenko LM, Nadgornaia VA, Kriachok IA. [Immunocytochemistry in tumor diagnosis]. Kyiv: Morion; 2003. Russian.

Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses. Behav Res Methods. 2009; 41: 1149-60. https://doi.org/10.3758/BRM.41.4.1149

Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001; 357:539-545. https://doi.org/10.1016/S0140-6736(00)04046-0

Vit VV. [Tumor pathology of the eye]. Odesa: Astroprint; 2009. Russian.

Yang JC, Rosenberg SA. Adoptive T-Cell Therapy for Cancer. Adv Immunol. 2016. 130: 279-294. https://doi.org/10.1016/bs.ai.2015.12.006